{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-026715","form_type":"8-K","ticker":"NTRA","cik":"0001604821","company_name":"Natera, Inc.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.803508+00:00","generated_at":"2026-06-18T22:12:57.937225+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Natera Q4 revenue $217.3M (+25.6% YoY); net loss $142.6M; guides 2023 rev $980M-$1B","bullets":["Q4 total revenue $217.3M (+25.6% YoY); product revenue $212.9M (+28.2%); tests processed 559,700 (+27.6%).","Full-year 2022 revenue $820.2M (+31.1% YoY); net loss $547.8M ($5.57/diluted) vs $471.7M ($5.21) in 2021.","Oncology tests 196,000 in 2022 (+158% YoY); 40 peer-reviewed studies for Signatera published.","2023 guidance: revenue $980M-$1B; gross margin 41%-44%; net cash consumption $300M-$325M.","Appointed Ruth Williams-Brinkley to board effective March 2, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-026715","json":"https://secwatch.observer/filing/0001104659-23-026715.json","markdown":"https://secwatch.observer/filing/0001104659-23-026715.md","text":"https://secwatch.observer/filing/0001104659-23-026715.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604821/000110465923026715/0001104659-23-026715-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604821/000110465923026715/tm238033d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T22:12:57.937225+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}